US2012135036A1PendingUtilityA1

Bacterial composition and its use

50
Assignee: DENNIN VERONIQUEPriority: Dec 5, 2002Filed: Oct 28, 2011Published: May 31, 2012
Est. expiryDec 5, 2022(expired)· nominal 20-yr term from priority
Inventors:Véronique DenninGregory LeyerAnnick MercenierSophie NuttenBruno Pot
A61P 37/02A61P 37/04A61P 37/08A61P 37/00A61P 29/00A61P 1/00C12N 1/20A61K 35/747A61K 35/745C12R 2001/25C12R 2001/23C12R 2001/225C12R 2001/01C12N 1/205
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

Claims

exact text as granted — not AI-modified
1 . A bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of  Lactobacillus acidophilus  PTA-4797 , Lactobacillus plantarum  PTA-4799 , Lactobacillus salivarius  PTA-4800 , Lactobacillus paracasei  PTA-4798 , Bifidobacterium bifidum  PTA-4801 and  Bifidobacterium lactis  PTA-4802. 
     
     
         2 . The bacterial composition according to  claim 1 , wherein the strains is selected from the group consisting of  Lactobacillus acidophilus  PTA-4797 , Lactobacillus plantarum  PTA-4799, and  Bifidobacterium lactis  PTA-4802. 
     
     
         3 . The bacterial composition according to  claim 1  wherein the strain is  Lactobacillus acidophilus  PTA-4797. 
     
     
         4 . The bacterial composition according to  claim 1  wherein the strain is  Lactobacillus plantarum  PTA-4799. 
     
     
         5 . The bacterial composition according to  claim 1  wherein the strain is  Bifidobacterium lactis  PTA-4802. 
     
     
         6 . The bacterial composition according to  claim 1  comprising at least 2 strains selected from the group consisting of  Lactobacillus acidophilus  PTA-4797 , Lactobacillus plantarum  PTA-4799 , Lactobacillus salivarius  PTA-4800 , Lactobacillus paracasei  PTA-4798 , Bifidobacterium bifidum  PTA-4801 and  Bifidobacterium lactis  PTA-4802. 
     
     
         7 . The bacterial composition according to  claim 1  comprising at least 3 strains selected from the group consisting of  Lactobacillus acidophilus  PTA-4797 , Lactobacillus plantarum  PTA-4799 , Lactobacillus salivarius  PTA-4800 , Lactobacillus paracasei  PTA-4798,  Bifidobacterium bifidum  PTA-4801 and  Bifidobacterium lactis  PTA-4802. 
     
     
         8 . The bacterial composition according to  claim 1  comprising a blend of  Lactobacillus acidophilus  PTA-4797,  Lactobacillus plantarum  PTA-4799 , Lactobacillus salivarius  PTA-4800 , Lactobacillus paracasei  PTA-4798 , Bifidobacterium lactis  PTA-4802 and  Bifidobacterium bifidum  ETA-4801. 
     
     
         9 . The bacterial composition according to any one of the preceding claims, characterized in that it comprises from 10 6  to 10 11  CFU of bacteria/g of composition. 
     
     
         10 . The bacterial composition according to any one of the preceding claims, characterized in that it comprises from 10 8  to 10 11  CFU of bacteria/g of composition. 
     
     
         11 . The bacterial composition according to any one of the preceding claims, characterized in that the composition is useful for the prevention and/or the reduction of inflammatory bowel disease. 
     
     
         12 . The bacterial composition according to any one of the preceding claims, characterized in that the composition is useful for maintaining the homeostasis of the immune system. 
     
     
         13 . The bacterial composition according to any one of the preceding claims, characterized in that the composition is useful for the prevention and/or the reduction of allergenicity. 
     
     
         14 . The bacterial composition according to any one of the preceding claims, characterized in that the composition is useful as immunoadjuvent. 
     
     
         15 . An immunomodulation method comprising the step of using at least one strain selected from the group consisting of  Lactobacillus acidophilus  PTA-4197 , Lactobacillus plantarum  PTA-4799 , Lactobacillus salivarius  PTA-4800 , Lactobacillus paracasei  PTA-4798 , Bifidobacterium bifidum  PTA-4801 and  Bifidobacterium lactis  PTA-4802. 
     
     
         16 . Food, dietary supplement or pharmaceutical composition comprising the composition according to one of  claims 1  to  14 . 
     
     
         17 . Composition according to  claim 16 , characterized in that it is a dairy product. 
     
     
         18 . Composition according to  claim 16  or  17 , characterized in that it is an infant formula. 
     
     
         19 . Composition according to  claims 16  to  18 , wherein the composition has immunomodulation properties. 
     
     
         20 . Pharmaceutical composition comprising the composition according to  claims 1  to  14  useful for the prevention of inflammatory bowel disease. 
     
     
         21 . Pharmaceutical composition comprising the composition according to  claims 1  to  14  useful for immunomodulation.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.